Generic Name: Timoptic
What is Timoptic?
In addition, platelet aggregation may be impaired by selective serotonin reuptake inhibitors SSRIs due to platelet serotonin depletion, possibly increasing the risk of a bleeding complication e. Patients should be instructed to monitor for signs and symptoms of citalopram-related adverse events and bleeding while taking an SSRI concurrently with ticlopidine and to promptly report any bleeding events to the practitioner.
Cladribine: Due to the thrombocytopenic effects of purine analogs, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors. Clobazam: A dosage reduction of clobazam may be necessary during co-administration of ticlopidine. Clofarabine: Due to the thrombocytopenic effects of antineoplastics an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors.
Clopidogrel: Because clopidogrel inhibits platelet aggregation, a potential additive risk for bleeding exists if clopidogrel is given in combination with other drugs that affect hemostasis such as platelet inhibitors. Also, coadministration of clopidogrel and ticlopidine should be avoided. Furthermore, ticlopidine is a CYP2C19 inhibitor, and clopidogrel requires hepatic biotransformation via CYP2C19 to its active metabolite.
Without ADP, fibrinogen does not bind to the platelet surface, preventing platelets from sticking to each other. Therefore, new platelets must be formed before platelet function normalizes. After the first dose the half life is 12. Clearance is also slower in the elderly. It increases the antiplatelet effects of aspirin and other NSAIDs.
Ticlopidine Aspirin Stroke Study Group". N Engl J Med. Stent Anticoagulation Restenosis Study Investigators". Please review the contents of the section and add the appropriate references if you can.
Unsourced or poorly sourced material may be challenged and removed. Generic Name: ticlopidine tye-KLOE-pi-deen Brand Name: TiclidTiclopidine can cause serious and sometimes life-threatening blood disorders. Symptoms may appear within the first few days of taking ticlopidine.
How should I take Timoptic?
Antithymocyte Globulin: An increased risk of bleeding may occur when platelet inhibitors are used with agents that cause clinically significant thrombocytopenia, such as antithymocyte globulin. Platelet inhibitors should be used cautiously in patients with thrombocytopenia following the administration of antithymocyte globulin or other drugs that cause significant thrombocytopenia due to the increased risk of bleeding. Apixaban: The concomitant use of apixaban and platelet inhibitors e.
In the ARISTOTLE trial comparative trial of apixaban and warfarin in patients with nonvalvular atrial fibrillationconcomitant use of aspirin increased the bleeding risk of apixaban from 1.
If given concomitantly, patients should be educated about the signs and symptoms of bleeding and be instructed to report them immediately or go to an emergency room.
What should I avoid while taking Timoptic?
Your Personal Message Send Message Share on Social Media Ticlopidine and ClopidogrelMartin J. Dallas, TX 75231 Customer Service 1-800-AHA-USA-1 1-800-242-8721 Local Info Contact Us About Us Our mission is to build healthier lives, free of cardiovascular diseases and stroke. PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program BBB Accredited Charity Comodo Secured.
Platelets are a type of blood cells that help in clotting blood. Ticlopidine prevents abnormal blood clotting by inhibiting platelets from clumping together. Due to its this property, the drug is useful for preventing stroke in patients who already had a stroke or those who are at risk of having one.
It can also be used to prevent formation of blood clots in people with coronary stents, it as a metal tube that is inserted in clogged blood vessels using surgery, to keep the flow of blood uninterrupted.
Timoptic side effects
Dalteparin: Because ticlopidine inhibits platelet aggregation, a potential additive risk for bleeding exists if ticlopidine is given in combination with other agents that affect hemostasis such as anticoagulants. Danaparoid: Because ticlopidine inhibits platelet aggregation, a potential additive risk for bleeding exists if ticlopidine is given in combination with other agents that affect hemostasis such as anticoagulants. Dasatinib: Due to the thrombocytopenic and possible platelet inhibiting effects of dasatinib, an additive risk of bleeding may be seen in patients receiving concomitant platelet inhibitors.
Defibrotide: Coadministration of defibrotide with antithrombotic agents anticoagulants and platelet inhibitors and fibrinolytics thrombolytic agents is contraindicated. The pharmacodynamic activity and risk of hemorrhage with antithrombotics e. If therapy with defibrotide is necessary, discontinue systemic anticoagulant or fibrinolytic therapy not including use for routine maintenance or reopening of central venous catheters prior to initiation of defibrotide therapy.
Common Timoptic ide effects may include:
Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy study.
Discuss the risks and benefits with your doctor.
There is good evidence to indicate the presence of a third as yet unidentified ADP receptor.
This is to make sure no blood cell problems such as those described above occur.
The risk or severity of adverse effects can be increased when Ticlopidine is combined with Apixaban. The risk or severity of adverse effects can be increased when Ticlopidine is combined with Balsalazide.
The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Ticlopidine resulting in a loss in efficacy. The risk or severity of adverse effects can be increased when Ticlopidine is combined with Deoxycholic Acid.
The risk or severity of adverse effects can be increased when Ticlopidine is combined with Diflunisal.
Where can I get more information?
In patients with intermittent claudication.
CrossRefPubMedGoogle ScholarUrban P, Macaya C, Rupprecht HJ, Kiemeneij F, Emanuelsson H, Fontanelli A, Pieper M, Wesseling T, Sagnard L: Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting MATTIS.